Evidence map›Paper›PMID 41916932›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

SCOUT: An Exploratory Approach to Scouting Dose-Relevant Covariates.

Yasuhisa Ideno, Hidefumi Kasai, Yusuke Tanigawara

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yasuhisa IdenoOffice of New Drug IV, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.ORCID https://orcid.org/0009-0001-1710-0839
Hidefumi KasaiLaboratory of Pharmacometrics and Systems Pharmacology, Keio Frontier Research and Education Collaboration Square (K-FRECS) at Tonomachi, Keio University, Kawasaki, Kanagawa, Japan.ORCID https://orcid.org/0000-0001-5231-8027
Yusuke TanigawaraLaboratory of Pharmacometrics and Systems Pharmacology, Keio Frontier Research and Education Collaboration Square (K-FRECS) at Tonomachi, Keio University, Kawasaki, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-6309-955X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identifying the clinically relevant covariates that drive inter-individual variability is fundamental to precision dosing. However, standard approaches such as stepwise covariate modeling are often limited by the laborious process of evaluating numerous covariate-parameter relationships and primarily focus on statistical significance rather than the clinical relevance of covariate effects on dosing requirements. To address these limitations, we developed the Systematic Covariate Observational Uncovering Technique (SCOUT), an approach that streamlines covariate exploration by shifting the focus from influences on multiple pharmacokinetic (PK) or pharmacodynamic (PD) parameters to those on individual optimal dose, which is a clinically essential metric. This shift simplifies the analysis from a complex many-to-many relationship to a one-to-many evaluation, facilitating rapid identification of factors that substantially influence therapeutic effects. We validated SCOUT across three distinct scenarios: simulation-based verification, real-world amikacin PK data analysis, and complex eribulin PK/PD modeling. Estimated individual optimal doses matched theoretical values with minimal bias. Real-world applications successfully revealed established covariates such as weight and renal function for amikacin and baseline neutrophil count for eribulin. Furthermore, SCOUT provided objective evidence for dosing-interval optimization. By serving as an efficient hypothesis-generating approach, SCOUT enables pharmacometricians to prioritize clinically impactful factors and rationally narrow the search space in formal model building. This approach functions as a "nautical chart" in navigation toward optimal dosing, ultimately supporting more rational and efficient clinical decision-making in drug development and precision medicine.

Indexed as

AmikacinAnti-Bacterial AgentsModels, BiologicalComputer SimulationDose-Response Relationship, DrugHumansAmikacinAnti-Bacterial Agentsdose optimizationdrug developmentempirical Bayes estimatespharmacodynamicspharmacometricspopulation pharmacokinetics

Identifiers

PMID41916932
PMCPMC13140994

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.